Vincent has more than 40 years’ experience in the biotechnology industry in a broad range of functions. He identifies and invests in new businesses and supports portfolio companies. His recent Board positions have included IFM Therapeutics, IFM Tre, IFM Due, Personalis and Hydra Biosciences, and he is also an observer on the Boards of Nido Biosciences and Atsena Therapeutics. Earlier Board positions included Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Magellan Diagnostics and PrimeraDx. Before joining Abingworth in 2007 he was Senior Vice President, Business Development, of Alnylam Pharmaceuticals (a former Abingworth portfolio company).
Previously, Vincent was at Millennium Pharmaceuticals where he held VP positions in business development, strategic planning and corporate communications. Earlier, he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia. He began his career in R&D at Amersham International. He has a BSc in Biochemistry and a PhD in Biochemical Embryology (molecular biology) from University College London.
